drugset / Trial / NCT00258050

To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients

NCT00258050

Phase 1 Completed 24 enrolled GlaxoSmithKline
RandomizedCrossoverOpen-labelTreatment

Summary

To characterize the effect of repeat oral dose of lapatinib treatment on the pharmacokinetics of a single oral and single intravenous dose of midazolam in adult cancer patients. Also to assess the safety and tolerability of chronic oral lapatinib therapy in cancer patients.

Timeline

Start
2005-11-21
Primary completion
2007-02-08
Completion
2007-02-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Lapatinib Small molecule 1500 mg Oral
Subject Midazolam Small molecule 3 mg Oral

Indications